Ken Griffin Relay Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$6.23 - $9.51 $1,246 - $1,902	-200 Reduced 11.76%	1,500 $10,000
Q2 2024 Aug 14, 2024	SELL	$5.9 - $8.02 $14,750 - $20,050	-2,500 Reduced 59.52%	1,700 $11,000
Q1 2024 May 15, 2024	BUY	$7.5 - $12.07 $17,250 - $27,761	2,300 Added 121.05%	4,200 $34,000
Q4 2023 Feb 14, 2024	SELL	$6.01 - $11.48 $32,454 - $61,992	-5,400 Reduced 73.97%	1,900 $20,000
Q3 2023 Nov 14, 2023	SELL	$8.24 - $12.97 $13,184 - $20,752	-1,600 Reduced 17.98%	7,300 $61,000
Q2 2023 Aug 14, 2023	SELL	$9.99 - $18.27 $161,838 - $295,974	-16,200 Reduced 64.54%	8,900 $111,000
Q1 2023 May 15, 2023	BUY	$15.0 - $22.76 $256,500 - $389,196	17,100 Added 213.75%	25,100 $413,000
Q4 2022 Feb 14, 2023	SELL	$14.16 - $24.02 $2.32 Million - $3.93 Million	-163,800 Reduced 95.34%	8,000 $119,000
Q3 2022 Nov 14, 2022	SELL	$18.07 - $31.37 $1.21 Million - $2.1 Million	-66,900 Reduced 28.03%	171,800 $3.84 Million

204

156M

207K

40K

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $577M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.